Season 1 Episode 12 GeneproDX
Years operating: 7 years
Number of Employees: 51
Business Industry: Healthcare
Business type: B2B & B2CÂ
Menu
Years operating: 7 years
Number of Employees: 51
Business Industry: Healthcare
Business type: B2B & B2CÂ
ABOUT US
GeneproDX is transforming traditional medicine —bridging Health Tech and AI and providing patients with fast, reliable, and accurate diagnostics..
SUMMARY
GeneproDX is transforming traditional medicine —bridging Health Tech and AI and providing patients with fast, reliable, and accurate diagnostics. GeneproDX’s patented product, ThyroidPrint, is widely used by doctors in Latin America with plans for expansion to the U.S. and Europe in 2022. ThyroidPrint provides highly-accurate diagnosis, resulting in fewer unnecessary surgeries — saving patients from life-altering surgical outcomes.
OUR ADVANTAGES
GeneproDX is bringing cutting-edge diagnostics to patients by providing the first and only globally available diagnostic test for patients with indeterminate thyroid nodules (ThyroidPrint). We will offer a seamless sample-to-insight testing in under 48 hours by using a globally Idylla available diagnostic platform, providing access to hundreds of thousands of underserved patients around the world.
NO CATCH. NO RISK. NO-BRAINER!
Boost your crypto portfolio with 100 free Unicoins. Use promo code below to get your certificate.
Promo Code
UNICORNS
Any historical returns, expected returns, or probability projections may not reflect actual future performance. These examples are extreme and rare examples of returns that have been realized. It should not be assumed that these types of results are common or that they should be expected. Investing in private companies offers the opportunity to earn a high return on your investment, but also carries significant risks, including lack of liquidity and potential loss of some or all of your investment. Past performance is no guarantee of future results. Please refer to Risks and Disclaimers to learn more about the risks associated with investing in private companies.
